Amryt Pharma (AMYT)

Amryt Pharma Stock Price & Analysis


AMYT Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$5.61 - $11.63
Previous Close$7.3
Average Volume (3M)30.88K
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$83.25M
Total Debt (Recent Filing)$212.79M
Price to Earnings (P/E)-18.7
Next EarningsMar 08, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
EPS (TTM)-0.39
Shares Outstanding63,971,689
Standard Deviation0.12
10 Day Avg. Volume55,085
30 Day Avg. Volume30,878
Price to Book (P/B)-2.54
Price to Sales (P/S)0.02
Price to Cash Flow (P/CF)4.40
P/FCF Ratio5.10
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target Upside153.42% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4


Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Amryt Pharma’s price range in the past 12 months?
Amryt Pharma lowest stock price was $5.61 and its highest was $11.63 in the past 12 months.
    What is Amryt Pharma’s market cap?
    Currently, no data Available
    When is Amryt Pharma’s upcoming earnings report date?
    Amryt Pharma’s upcoming earnings report date is Mar 08, 2023 which is in 102 days.
      How were Amryt Pharma’s earnings last quarter?
      Amryt Pharma released its earnings results on Nov 03, 2022. The company reported -$0.06 earnings per share for the quarter, missing the consensus estimate of -$0.028 by -$0.032.
        Is Amryt Pharma overvalued?
        According to Wall Street analysts Amryt Pharma’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Amryt Pharma pay dividends?
          Amryt Pharma does not currently pay dividends.
          What is Amryt Pharma’s EPS estimate?
          Amryt Pharma’s EPS estimate is -$0.04.
            How many shares outstanding does Amryt Pharma have?
            Amryt Pharma has 64,139,960 shares outstanding.
              What happened to Amryt Pharma’s price movement after its last earnings report?
              Amryt Pharma reported an EPS of -$0.06 in its last earnings report, missing expectations of -$0.028. Following the earnings report the stock price went up 2.309%.
                Which hedge fund is a major shareholder of Amryt Pharma?
                Among the largest hedge funds holding Amryt Pharma’s share is Highbridge Capital Management LLC. It holds Amryt Pharma’s shares valued at 44M.


                  Amryt Pharma Stock Smart Score

                  The Amryt Pharma stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Amryt Pharma

                  Amryt Pharma PLC is a specialty pharmaceutical company. It is focused on developing and delivering new treatments to help improve the lives of patients with rare or orphan diseases. It holds an exclusive license to sell Lojuxta (lomitapide) for adults, across the European Union and other territories including the Middle East, North Africa, Turkey and Israel. Lojuxta is used to treat a rare life-threatening disease called Homozygous Familial Hypercholesterolemia. Myalept (metreleptin) is an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients. It derives most of the revenue from the European Economic Area (EEA).


                  Forecast EPS vs Actual EPS

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis